PURPOSE OF REVIEW: The present review updates the current status of research for induction of tolerance through a mixed chimerism approach in nonhuman primates and humans. RECENT FINDINGS: Allograft tolerance has been successfully achieved with a nonmyeloablative conditioning regimen and donor bone marrow transplantation in human leukocyte antigen (HLA)-matched and mismatched kidney transplantation. In HLA-matched kidney transplantation, persistent mixed chimerism and renal allograft tolerance has been achieved in some patients. In HLA-mismatched combinations, induction of persistent mixed chimerism has not been achieved using a nonmyeloablative preparative regimen. Nevertheless, the transient mixed chimerism that has been achieved has resulted in long-term renal allograft tolerance in the majority of patients. Recent preclinical studies have demonstrated that the presence of heterologous memory T-cell responses observed in primates, but not in rodents, may be a major barrier for induction of durable chimerism and tolerance in primates. Strategies to overcome such memory T-cell responses may, therefore, be of great value in the development of reliable protocols for clinical tolerance induction. SUMMARY: Induction of tolerance in clinical kidney transplantation has been achieved via mixed chimerism approaches. Improvements in the consistency and safety of tolerance induction and extension of successful protocols to other organs and to organs from deceased donors will all be among the next steps in bringing tolerance to a wider range of clinical applications.
PURPOSE OF REVIEW: The present review updates the current status of research for induction of tolerance through a mixed chimerism approach in nonhuman primates and humans. RECENT FINDINGS: Allograft tolerance has been successfully achieved with a nonmyeloablative conditioning regimen and donor bone marrow transplantation in human leukocyte antigen (HLA)-matched and mismatched kidney transplantation. In HLA-matched kidney transplantation, persistent mixed chimerism and renal allograft tolerance has been achieved in some patients. In HLA-mismatched combinations, induction of persistent mixed chimerism has not been achieved using a nonmyeloablative preparative regimen. Nevertheless, the transient mixed chimerism that has been achieved has resulted in long-term renal allograft tolerance in the majority of patients. Recent preclinical studies have demonstrated that the presence of heterologous memory T-cell responses observed in primates, but not in rodents, may be a major barrier for induction of durable chimerism and tolerance in primates. Strategies to overcome such memory T-cell responses may, therefore, be of great value in the development of reliable protocols for clinical tolerance induction. SUMMARY: Induction of tolerance in clinical kidney transplantation has been achieved via mixed chimerism approaches. Improvements in the consistency and safety of tolerance induction and extension of successful protocols to other organs and to organs from deceased donors will all be among the next steps in bringing tolerance to a wider range of clinical applications.
Authors: Kenneth A Newell; Adam Asare; Allan D Kirk; Trang D Gisler; Kasia Bourcier; Manikkam Suthanthiran; William J Burlingham; William H Marks; Ignacio Sanz; Robert I Lechler; Maria P Hernandez-Fuentes; Laurence A Turka; Vicki L Seyfert-Margolis Journal: J Clin Invest Date: 2010-05-24 Impact factor: 14.808
Authors: R M Welsh; T G Markees; B A Woda; K A Daniels; M A Brehm; J P Mordes; D L Greiner; A A Rossini Journal: J Virol Date: 2000-03 Impact factor: 5.103
Authors: T Kawai; A Poncelet; D H Sachs; S Mauiyyedi; S Boskovic; S L Wee; D S Ko; A Bartholomew; M Kimikawa; H Z Hong; G Abrahamian; R B Colvin; A B Cosimi Journal: Transplantation Date: 1999-12-15 Impact factor: 4.939
Authors: Y Fuchimoto; C A Huang; K Yamada; A Shimizu; H Kitamura; R B Colvin; V Ferrara; M C Murphy; M Sykes; M White-Scharf; D M Neville; D H Sachs Journal: J Clin Invest Date: 2000-06 Impact factor: 14.808
Authors: Christian Morath; Anita Schmitt; Florian Kälble; Martin Zeier; Michael Schmitt; Flavius Sandra-Petrescu; Gerhard Opelz; Peter Terness; Matthias Schaier; Christian Kleist Journal: Pediatr Nephrol Date: 2017-02-23 Impact factor: 3.714
Authors: Sulemon Chaudhry; Yojiro Kato; Joshua Weiner; Paula Alonso-Guallart; Sam Baker; David C Woodland; Jay H Lefkowitch; Raimon Duran-Struuck; Hugo P Sondermeijer; Jonah Zitsman; Mallory L Sears; Anette Wu; Brian Karolewski; Philipp J Houck; Mercedes Martinez; Tomoaki Kato; Megan Sykes; Adam D Griesemer Journal: Transplantation Date: 2020-04-06 Impact factor: 4.939
Authors: Joseph Leventhal; Michael Abecassis; Joshua Miller; Lorenzo Gallon; Kadiyala Ravindra; David J Tollerud; Bradley King; Mary Jane Elliott; Geoffrey Herzig; Roger Herzig; Suzanne T Ildstad Journal: Sci Transl Med Date: 2012-03-07 Impact factor: 17.956
Authors: J Rodrigo Diaz-Siso; Ericka M Bueno; Geoffroy C Sisk; Francisco M Marty; Bohdan Pomahac; Stefan G Tullius Journal: Clin Transplant Date: 2013-04-14 Impact factor: 2.863
Authors: Joseph Leventhal; Michael Abecassis; Joshua Miller; Lorenzo Gallon; David Tollerud; Mary Jane Elliott; Larry D Bozulic; Christopher Houston; Nedjema Sustento-Reodica; Suzanne T Ildstad Journal: Transplantation Date: 2013-01-15 Impact factor: 4.939
Authors: Scott S Graves; David W Mathes; George E Georges; Christian S Kuhr; Jeff Chang; Tiffany M Butts; Rainer Storb Journal: Transplantation Date: 2012-09-27 Impact factor: 4.939